We are a leading innovative oncology molecular diagnostics and testing company in China. Our proprietary technology spans the full spectrum of molecular testing, and we lead the competition in China in adopting a multi-omics approach that enables the comprehensive testing for cancer risk, early detection, therapy selection, and monitoring for cancer relapse.      

We are the pioneer in developing diagnostic tools for cancer prognosis and monitoring in China with the largest market share of 36.8% in terms of revenue of next-generation sequencing (“NGS”) based prognosis and monitoring in 2021, and launched the country’s first molecular residual disease (“MRD”) detection service, Genecast MRD – Lung.